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Abstract
Background—To investigate the effect of helminth infections and their treatment during
pregnancy on HIV load, we conducted a 2×2 factorial randomised controlled trial of albendazole
versus placebo and praziquantel versus placebo in pregnant women in Entebbe, Uganda
Methods—Two hundred and sixty-four HIV-infected women from the Entebbe Mother and Baby
Study (ISRCTN32849447) were included in this analysis. Women were tested for helminth
infections at enrolment and mean HIV load was compared between infected and uninfected
groups. The effect of anthelminthic treatment on HIV load was evaluated at six weeks post-
treatment and at delivery using linear regression and adjusting for enrolment viral load.
Results—Hookworm and Trichuris infections were associated with higher mean viral load at
enrolment (adjusted mean difference 0.24log10 copies/ml, 95% confidence interval (CI): 0.01 to
0.47, p=0.03 and 0.37log10 copies/ml, 95%CI: 0.00 to 0.74, p=0.05, respectively). There were no
associations between viral load and other helminth species. There was some evidence that
albendazole reduced viral load at six weeks post-treatment (adjusted mean difference −0.17, 95%
CI: −0.36 to 0.01, p=0.07), however this effect did not differ according to mother’s hookworm
infection status and had diminished at delivery (adjusted mean difference −0.11, 95% CI: −0.28 to
0.07, p=0.23). There was no effect of praziquantel treatment on HIV load at any time point.
Conclusions—Infection with some soil-transmitted helminth species is associated with
increased HIV load in pregnancy. Treatment with albendazole causes a small decrease in HIV
load, however this may not represent a direct effect of worm removal.
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Introduction
In 2010, 34 million people worldwide were estimated to be living with HIV, with 7000 new
infections daily 1. Antiretroviral therapy (ART) slows disease progression in people living
with HIV (PLHIV) by suppressing viral replication, and may prevent both horizontal and
vertical transmission of the disease 2,3. Current WHO guidelines are that ART be initiated in
all PLHIV with a CD4 count ≤350 cells/mm3 4. In addition, the provision of ART for the
prevention of mother-to-child transmission is recommended in all pregnant women with
HIV, regardless of their symptoms 5. Although there have been dramatic improvements in
treatment access over the last decade, 9 million individuals who are eligible to receive ART
are still estimated not to do so 1. In parallel with continued efforts to improve ART
coverage, other interventions that may impact on HIV disease progression and transmission
should be considered.
Sub-Saharan Africa bears a disproportionate burden of the HIV epidemic, with
approximately 68% of infected individuals estimated to live in the region 6. Co-infection
with other pathogens including helminths is common 7,8, and it has been suggested that
persistent co-infections may have a detrimental impact on PLHIV. Helminths have profound
effects on the host immune system, and these effects may spill over to impact on immune
responses to other pathogens 9. Specifically, helminth infection induces a prominent type 2
response profile which inhibits the type 1 response profile needed to combat and control
viral antigens such as HIV. It is hypothesised that removal of helminth infections, which can
be achieved with cheap and widely available anthelminthic treatments, would reverse these
associations.
Observational studies of the relationship between helminths and HIV have found conflicting
results 10-13 but a recent systematic review 14, pooled data from three randomised controlled
trials 15-17 and concluded there was evidence of a beneficial effect of anthelminthic
treatment on markers of HIV disease progression. Level of HIV load during pregnancy is a
key determinant of vertical transmission risk and there is some observational evidence for a
positive association between helminth infection and increased risk of mother-to-child
transmission of HIV 18, however we have previously reported finding no benefit of
anthelminthic treatment during pregnancy for vertical HIV transmission in a randomised
controlled trial 19. To further elucidate the relationship between helminth co-infection and
HIV, we report results from the same trial, investigating the impact of helminths and their
treatment during pregnancy on viral load in HIV infected women six weeks post-treatment
and after delivery.
Methods
Study area and participants
Participants were HIV infected pregnant women enrolled in the Entebbe Mother and Baby
Study (EMaBS; ISRCTN32849447) 20, a randomised controlled trial of anthelminthic
treatment during pregnancy conducted in Entebbe Municipality and Katabi subcounty, a
peninsula in Lake Victoria, Uganda, with a high burden of parasitic infections 21. Pregnant
women presenting at the government-funded antenatal clinic at Entebbe General Hospital,
who were resident in the study area, planning to deliver in the hospital, willing to know their
HIV status, and in the second or third trimester of pregnancy, were eligible for inclusion in
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EMaBS. Exclusion criteria were evidence of possible helminth-induced pathology
(haemoglobin <8g/dl, clinically apparent severe liver disease, diarrhoea with blood in stool),
history of adverse reaction to anthelminthics, prior enrolment in an earlier pregnancy or
abnormal pregnancy as assessed by the midwife.
The primary outcomes for EMaBS were response to immunisation and incidence of
infectious diseases in the offspring, and vertical transmission of HIV; results for these have
been reported elsewhere 19. In this analysis, we examine the effect of anthelminthic
treatment on HIV load in the HIV-1 positive mothers in the cohort. The primary outcome for
this analysis is viral load during pregnancy, measured at six weeks post treatment, with
secondary outcome viral load at delivery. Women were eligible for inclusion in this analysis
if they were HIV-1 positive and had viral load measured at enrolment and were excluded if
known to be taking ART.
Study design and procedures
After obtaining written, informed consent, demographic and clinical details were recorded,
blood samples obtained and women requested to return with a stool sample. Women were
then randomised in a 1:1:1:1 ratio to single-dose albendazole 400 mg or matching placebo
and praziquantel 40 mg/kg or matching placebo in a 2×2 factorial design. The randomisation
code was generated by the trial statistician in blocks of 100. Sealed envelopes containing the
study intervention were prepared by colleagues at the Medical Research Council Unit in
Entebbe with no other involvement in the trial. Treatments were allocated in numerical order
by trained interviewer-counsellors and taken under observation. All participants and staff
were blinded to treatment allocation. After enrolment, women continued to receive standard
antenatal care, including haematinics, tetanus immunization, and intermittent presumptive
treatment for malaria (with sulfadoxine-pyrimethamine) after the first trimester.
Prior to the start of the project, a programme for prevention of mother-to-child HIV
transmission was established at Entebbe Hospital. In accordance with guidelines current at
the time, HIV positive women were counselled and given intrapartum and neonatal single-
dose nevirapine for prevention of mother-to-child HIV transmission 22. From March 2005
onwards, when ART provision became available, HIV infected women were offered a repeat
full blood count and CD4 T cell count and referred to the Entebbe Hospital ART services if
indicated. Those for whom ART was not yet indicated at enrolment had repeat CD4 counts
performed annually (or earlier if clinically indicated), to allow referral when necessary.
Blood samples were collected six weeks after enrolment from mothers who had not yet
delivered . Blood samples were also collected from the mother after delivery, and from cord
blood. Blood samples were taken from offspring of HIV infected women at six weeks and
18 months of age to assess their HIV-1 status.
Stool samples were collected approximately six weeks after delivery to assess effectiveness
of anthelminthic treatment; thereafter all mothers were treated with both praziquantel and
albendazole.
Parasitology and virology
Stool samples were examined for helminth ova using the Kato-Katz method 23 and by
charcoal culture for Strongyloides 24; two Kato-Katz slides were prepared from each sample
and examined within 30 minutes for hookworm ova, the following day for other species.
Urine examination for S. haematobium was not conducted due to the low prevalence of this
species in the study area. Hookworm and Schistosoma mansoni infections were classified
into low, medium and high intensities according to WHO guidelines 25,26. Blood samples
were examined by a modified Knott’s method for Mansonella perstans 27 and by thick film
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for malaria parasites. Quality control for Kato-Katz analyses was provided by the Vector
Control Programme of the Ministry of Health, Uganda, and for malaria parasitology through
the United Kingdom National External Quality Assessment Schemes.
HIV serology was performed for mothers by rapid test algorithm 28. For viral load
assessment, plasma and whole blood cell pellet were separated by centrifugation and stored
at −80°C until assays were performed. Plasma HIV load was measured using either Bayer
Versant branched DNA assay version 3.0 (Bayer HealthCare, Germany) or Roche Amplicor
HIV-1 RNA Monitor test Version 1.5 (Roche Molecular Systems Inc., USA). Methods used
to detect HIV-1 proviral DNA in infants at six weeks are described elsewhere 19. Eighteen
month samples were tested for HIV using rapid test algorithm.
Ethical approval
Ethical approval was given by the Uganda Virus Research Institute, Uganda National
Council for Science and Technology, and the London School of Hygiene & Tropical
Medicine.
Statistical analysis
The sample size for EMaBS was determined for the primary outcomes of the full trial 20.
Data were double entered into Microsoft Access (Redmond, WA, USA) and analysed using
Stata version 11 (College Station, TX, USA). Viral load data were log10 transformed for
analysis. Baseline characteristics of the mothers included in this study were summarised
overall and by randomisation arm.
An observational analysis of the association between infection with each helminth and HIV
load was conducted by comparing log10 viral load enrolment samples from mothers with
and without infection, using linear regression with adjustment for potential confounders
(CD4 count, age, asymptomatic malaria infection at enrolment) to calculate mean
differences with 95% confidence intervals. Likelihood ratio tests were used to calculate p-
values.
Trial analysis was done by intention-to-treat. The effects of albendazole treatment and of
praziquantel treatment on HIV load in mothers at six weeks post-treatment and at delivery
were examined separately using linear regression, including treatment group as a covariate
and adjusting for baseline (enrolment) viral load, and any factors that showed imbalance
between treatment arms and that were thought, a priori, likely to impact on viral load. Since
the study was designed as a factorial trial, we checked for interaction between albendazole
and praziquantel treatments on the two viral load outcomes by fitting interaction terms in
regression models.
Since not all women were infected with all helminths at enrolment, a planned subgroup
analysis was conducted, comparing the effect of albendazole treatment versus placebo in
women who had hookworm (the most prevalent helminth treated by albendazole) at
enrolment, and the effect of praziquantel treatment versus placebo in women who had S.
mansoni at enrolment, using linear regression models adjusted for baseline HIV-1 load and
any factors that showed imbalance between treatment arms. Differences between subgroups
were examined by fitting interaction terms in regression models. All p-values are two-sided
with no adjustment made for multiple comparisons.
Results
Between April 2003 and November 2005, 2507 women were enrolled in EMaBS. Of these,
299 (12%) tested positive for HIV. Five women on HAART and 30 women for whom no
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viral load measurement was available at enrolment were excluded from the analysis, leaving
264 women suitable for inclusion (Figure 1). Women who were HIV infected were on
average older, less educated, more likely to be widowed or divorced, to already have
children, and to be infected with asymptomatic malaria, and less likely to be infected with
hookworm, compared to HIV negative women. At enrolment, 67% of the 264 women were
infected with at least one helminth species, with individual prevalences: hookworm 39%,
Mansonella perstans 23%, Schistosoma mansoni 18%, Strongyloides stercoralis 11%,
Trichuris trichiura 9%, Ascaris lumbricoides 2%. The prevalences of all helminth species
other than hookworm were comparable between HIV infected and uninfected women 21.
Helminth infections were generally mild amongst HIV infected women: of hookworm
infections, 92% were classified as light (<1000 eggs per gram of stool (epg); of S. mansoni
infections, 65% were light (<100 epg). Characteristics of the 264 women at enrolment were
broadly similar between the four randomisation arms (Table 1), with the exception that
women allocated to albendazole had lower mean HIV load, and were less likely to have
malaria parasitaemia. In addition, women allocated to albendazole were more likely to have
viral load quantified by the Bayer assay at six weeks post-treatment. These chance
imbalances were taken into account in the analysis. Numbers of serious adverse events are
reported elsewhere 29 and were distributed evenly between treatment groups.
Associations between helminth infections and HIV-1 load at enrolment
The mean (standard deviation, SD) viral load at baseline was 4.09 (0.93) log10 copies/mL.
The mean viral load in women infected with hookworm was 0.22 log10 higher than in
uninfected women (Table 2). After adjustment for age, CD4 count, and asymptomatic
malaria infection, the difference in viral load was 0.24 log10 (95% confidence interval [CI]:
0.01, 0.47; p=0.03). There was some evidence that women infected with T. trichiura had
higher mean viral loads than those who were uninfected (adjusted mean difference (95%
CI): 0.37 log10 (0.00, 0.74); p=0.05). There was no evidence of a difference in log10 viral
load for any other helminth infection (Table 2). For hookworm and S. mansoni, we found no
evidence of an association between infection intensity and viral load.
Effect of anthelminthic treatment on HIV-1 load during pregnancy and post-delivery
At six weeks post-enrolment, 41 women had given birth and one had miscarried. Of the
remaining 222 women, HIV-1 load measurements were obtained for 166 (75%) at a median
(IQR) of 42 (41-45) days after treatment; mean (SD) viral load was 4.06 (0.91) log10. Based
on the single stool samples after delivery, single-dose albendazole and praziquantel
treatments were estimated to be 81% and 63% effective in removing hookworm and S.
mansoni, respectively.
There was no evidence of interaction between albendazole and praziquantel treatments,
therefore the effects of each treatment were examined independently. At six weeks post-
treatment women who had received albendazole had lower mean viral load than those who
received placebo (mean difference −0.40 log10, 95% CI: −0.68, −0.13), however after
adjusting for baseline viral load, asymptomatic malaria and assay used for viral load
quantification at six weeks post-treatment, this difference was reduced to −0.17 log10 (95%
CI: −0.36, 0.01), p=0.07 (Table 3). The effect of albendazole treatment was similar in
women with hookworm infection at enrolment compared to those uninfected (interaction
p=0.44).
HIV load was measured in 234 (89%) women post-delivery, at a median (IQR) time of 105
(67-133) days post-treatment; this figure was comparable between treatment groups.
Adjusting for viral load and malaria parasitaemia at enrolment, the effect of albendazole
treatment on viral load had diminished compared to that observed at six weeks post-
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treatment during pregnancy (adjusted mean difference −0.11 log10 (95% CI: −0.28, 0.07;
p=0.23). There weres no effects of praziquantel treatment on viral load at either time point,
nor any evidence of a differential effect of either anthelminthic treatment by susceptible
helminth infection (Table 3).
Effect of anthelminthic treatment on HIV vertical transmission and viral load in cord blood
Amongst the 294 HAART-naïve women included in this analysis, 16 were lost to follow-up
before delivery, five had miscarriages and nine had stillbirths, leaving information available
on 264 live deliveries. We have previously reported that six-week blood samples were
available from 211 infants of whom 39 (18%) were diagnosed with HIV infection, and that
there were no effects of treatment with albendazole or praziquantel on vertical HIV
transmission 19. Two further HIV transmissions were detected in blood samples taken from
children at 18 months, inclusion of these transmissions in the analysis had no impact on
results.
Discussion
There are limited data on the relationship between HIV load and helminth infection during
pregnancy. We have previously shown, and confirmed in this analysis, that anthelminthic
treatment during pregnancy does not significantly reduce the risk of vertical transmission,
however this finding is in the context of three quarters of women taking nevirapine at
delivery, and power to detect small to moderate sized reductions in risk of vertical
transmission was limited. Therefore by analysing the effect of anthelminthic treatment on
viral load during pregnancy and at delivery, we sought to further understand the relationship
between helminths during pregnancy and factors that could lead to vertical transmission of
HIV.
We have shown that infection with the soil-transmitted intestinal helminths, hookworm and
T. trichiura, during pregnancy is associated with higher HIV load. However, although there
was some evidence that albendazole treatment led to a small reduction in viral load six
weeks after treatment, this was not sustained to delivery. There was no evidence for a role of
other helminth species in HIV load modulation, although power to detect associations for
species which were rare in our study population, such as A. lumbricoides, was limited,
therefore we cannot discount a role for this species in viral load modulation.
The size of the effect of albendazole treatment was modest, conferring a reduction of 0.17
log10 in viral load. However, modelling studies have shown that even small reductions in
HIV load at the population level could translate to reductions in disease incidence; for
example a decrease in viral load of 0.3log10 has been estimated to decrease HIV
transmission by 20% and HIV progression by 25% 30.
We found no differential effect of albendazole treatment on HIV load amongst mothers who
were diagnosed with hookworm infection at enrolment compared to mothers with no
detectable hookworm, raising questions about the mechanism of the effect of albendazole. If
the effect was mediated by hookworm removal, we would expect the benefit to be greatest
in the hookworm-infected women and to persist to delivery (since stool samples at delivery
showed a reduction in hookworm prevalence from 45 to 5% amongst women treated with
albendazole 29). One possible explanation is the low sensitivity of a single Kato Katz stool
sample31,32: women in the hookworm “uninfected” group may have had low intensity
hookworm infection, or infections with other albendazole-susceptible helminth species.
However data available from a subgroup of women in the study who provided three stool
samples indicate that sensitivity was high for hookworm. Albendazole treatment was not
effective in the treatment of T. trichiura, therefore the effect of albendazole treatment cannot
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be mediated through removal of this worm. Another possible explanation relates to the fact
that albendazole has a broad spectrum of action and may clear other infections such as
malaria 33,34 which may themselves impact on HIV load 35, thus an effect of anthelminthic
treatment is seen in both the helminth “infected” and “uninfected” mothers; in this case
weakening of the effect by the time of delivery could be accounted for by the provision of
intermittent presumptive treatment for malaria to all women in the latter part of pregnancy.
We found no evidence for a role of S. mansoni or M. perstans in HIV load modification, in
contrast to previous randomised trials that have shown a reduction in viral load after
treatment of schistosomiasis 15 and filariasis 16, and our own observational study which
showed a transient increase in viral load after treatment of schistosomiasis 13. For M.
perstans, this was not unexpected since the single-dose anthelminthic treatments
administered in this trial were not effective in its treatment, however praziquantel treatment
was 63% effective in treating S. mansoni thus we would have expected to see any important
effects of the removal of this worm.
An association between S. haematobium infection and HIV prevalence has been
documented 36,37, suggesting a role for this helminth species in HIV transmission
dynamics 38. We could not examine this possibility since S. haematobium was not prevalent
in the study area; similar studies conducted in regions where S. haematobium infection is
endemic are required to elucidate this relationship.
In conclusion, soil-transmitted helminth co-infections may play a role in HIV load
modulation during pregnancy, but we found no evidence for involvement of other helminth
species. Treatment with albendazole caused a small decrease in HIV load, however the
observation that this decrease occurred regardless of whether the mother had an
albendazole-susceptible worm taken together with the diminution of the effect of
albendazole treatment by delivery indicate that any impact of albendazole treatment on HIV
load may not be directly mediated through worm removal.
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Figure 1.
Flowchart of participants through the study
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Table 1
Characteristics of 264 HIV-1 infected women by treatment arm
Albendazole
+
praziquantel
Praziquantel
only
Albendazole
only Placebo
Number HIV infected women enrolled 67 54 64 79
Age in years
<20 9 (13%) 8 (15%) 9 (14%) 10 (13%)
20-24 23 (34%) 21 (39%) 18 (28%) 29 (37%)
25-29 18 (27%) 15 (28%) 23 (36%) 22 (28%)
≥30 17 (25%) 10 (19%) 15 (22%) 18 (23%)
Education
None 9 (13%) 1 (2%) 3 (5%) 5 (6%)
Primary 39 (58%) 33 (61%) 36 (56%) 45 (57%)
Secondary 12 (18%) 16 (30%) 22 (34%) 26 (33%)
Tertiary 7 (10%) 4 (7%) 3 (5%) 3 (4%)
Marital status
Married 49 (73%) 46 (85%) 52 (81%) 63 (80%)
Single 12 (18%) 5 (9%) 8 (13%) 9 (11%)
Widowed/divorced/separated 6 (9%) 3 (6%) 5 (6%) 7 (9%)
Gravidity
1 9 (13%) 10 (19%) 14 (22%) 11 (14%)
2-4 41 (61%) 30 (56%) 33 (52%) 50 (63%)
≥5 17 (25%) 14 (26%) 17 (27%) 18 (23%)
Helminth infections
Hookworm 20 (30%) 24 (44%) 25 (39%) 33 (42%)
S. mansoni 13 (19%) 8 (15%) 14 (22%) 13 (16%)
M. perstans 13 (19%) 14 (26%) 15 (23%) 20 (25%)
S. stercoralis (1mv) 10 (15%) 8 (15%) 4 (6%) 6 (8%)
T. trichiura 6 (9%) 4 (8%) 7 (11%) 7 (9%)
A. lumbricoides 1 (1%) 0 (0%) 3 (5%) 2 (3%)
Any helminth 42 (63%) 35 (65%) 44 (69%) 54 (69%)
Malaria parasitaemia (3 mv) a
Positive 7 (11%) 8 (15%) 8 (13%) 22 (28%)
CD4 count
<300 13 (19%) 10 (19%) 9 (14%) 14 (18%)
300-499 25 (37%) 11 (20%) 16 (25%) 19 (24%)
>=500 18 (27%) 19 (35%) 26 (41%) 30 (38%)
Not done 11 (16%) 14 (26%) 13 (20%) 16 (20%)
HIV-1 log10 load at enrolment
Mean (SD) 4.00 (0.91) 4.11 (0.96) 3.96 (0.85) 4.27 (0.96)
Assay used to measure HIV load at
baseline
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Albendazole
+
praziquantel
Praziquantel
only
Albendazole
only Placebo
Bayer 60 (90%) 49 (91%) 60 (94%) 68 (86%)
Roche 7 (10%) 5 (9%) 4 (6%) 11 (14%)
Assay used to measure HIV load at six
weeks post-treatment (166 samples
tested)
Bayer 16 (40%) 11 (34%) 19 (44%) 14 (27%)
Roche 24 (60%) 21 (66%) 24 (56%) 37 (73%)
Assay used to measure HIV load at
delivery (234 samples tested)
Bayer 59 (98%) 46 (100%) 56 (97%) 66 (94%)
Roche 1 (2%) 0 (0%) 2 (3%) 4 (6%)
a
mv=missing values
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